Alaunos Therapeutics Inc (FRA:WEK)
€ 1.41 0 (0%) Market Cap: 326.90 Mil Enterprise Value: 325.29 Mil PE Ratio: 0 PB Ratio: 1.08 GF Score: 60/100

Q1 2019 ZIOPHARM Oncology Inc Earnings Call Transcript

May 08, 2019 / 08:30PM GMT
Release Date Price: €3.82 (-8.61%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Ziopharm Oncology First Quarter 2019 Results Call. (Operator Instructions) I would now like to turn the conference over to your host, Mr. Chris Taylor, Vice President, Investor Relations, Corporate Communications. Sir, you may begin.

Christopher Taylor
ZIOPHARM Oncology, Inc. - VP of IR and Corporate Communications

Thank you, Bridget, good afternoon. Welcome to the Ziopharm Oncology conference call and webcast to review results for the first quarter of 2019. This afternoon, we filed our 10-Q and issued our Q1 news release, both of which are available in the Investors Section of our website, ziopharm.com.

During the course of this call, the company will make forward-looking statements, including statements regarding the potential therapeutic candidates in our development pipeline, regulatory status, financial information and business trends. Forward-looking statements are subject to numerous risks and uncertainties as described in our 10-Q and within other filings that we may make with the SEC.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot